Antiemetics revisited

Current Opinion in Oncology

Volumn 9, Issue 4, 1997, Pages 321-326

  Roila, Fausto ^a   Del Favero, Albano ^b  

^a Policlinico Hospital   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; DEXAMETHASONE; DOLASETRON MESILATE; GRANISETRON; LORAZEPAM; METHYLPREDNISOLONE; METOCLOPRAMIDE; METOPIMAZINE; ONDANSETRON; SEROTONIN 3 ANTAGONIST; TROPISETRON;

ANTIEMETIC ACTIVITY; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONSTIPATION; DRUG COST; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; HEADACHE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; VOMITING;

EID: 0030849169     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199709040-00003     Document Type: Review

References (31)

1. Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM, • Tattersall MHN: On the receiving end V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 1996. 7:189-195. An important study on the patient's perception of the severity of various chemotherapy-induced side effects.
2. Cunningham D, Dicato M, Verweij J, Crombez R, de Mulder P. du Bois A, •• Stewart A, Smyth J, Selby P, van Straelen D, Parideans R, McQuade B, McRae J: Optimum anti-emetic therapy for cisplatin induced emesis over repeat courses: ondansetron plus dexamethasone compared with metoclopramide, dexamethasone plus lorazepam. Ann Oncol 1996, 7:277-282. An important study confirming the superiority of ondansetron plus dexamethasone with respect to the high-dose metoclopramide combinations.
3. Italian Group for Antiemetic Research: Ondansetron + dexamethasone versus metoclopramide + dexamethasone + diphenhydramine in the prevention of cisplatin-induced emesis. Lancet 1992. 340:96-99.
4. Italian Group for Antiemetic Research: Differences in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy. J Clin Oncol 1993, 11:2396-2404.
5. Depierre A, Lebeau B, Chevallier B, Votan B: Efficacy of ondansetron, • methylprednisolone plus metopimazine in patients previously uncontrolled with dual therapy in cisplatin containing chemotherapy [abstract]. Ann Oncol 1996, 7 (suppl 5):134. The first double-blind study demonstrating that in patients failing at previous cycle with ondansetron plus methylprednisolone the addition of metopimazine increased the antiemetic efficacy substantially.
6. Kris MG, Gralla RJ, Tyson LB, Clark RA, Cirrincione C. Groshen S: Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989. 7:108-114.
7. Moreno I, Rosell R, Abad A, Barnadas A, Carles J, Ribelles N, Solano V, Font A: Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients. Eur J Cancer 1992, 28A:1344-1347.
8. The Italian Group for Antiemetic Research: Cisplatin-induced delayed emesis: pattern and prognostic factors during three subsequent cycles. Ann Oncol 1994, 5:585-589.
9. Navari RM, Madajewicz S, Anderson N, Tchekmedyian NS, Whaley W, Garewal H, Beck TM, Chang AY, Greenberg B, Caldwell KC, Huffman DH, Gould JR, Carron G, Ossi M, Anderson EM: Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol 1995, 13:2408-2416.
10. Gridelli C, Ianniello GP, Ambrosini G, Mustacchi G, Pedicini T. Farris A, • Jacobelli S, Rossi G, Boni C, D'Aprile M. De Lena M, Di Carlo A, Bonsignori M, Silingardi V, Catalano G. Mosconi M, Olivieri A. Bianco AR: Ondansetron vs ondansetron plus dexamethasone in the prophylaxis of delayed emesis over three courses of cisplatin chemotherapy: results of a double-blind randomised study [abstract]. Proc Am Soc Clin Oncol 1996, 15:545. A study demonstrating the superiority of ondansetron plus dexamethasone with respect to ondansetron alone in the prevention of cisplatin-induced delayed emesis.
11. Gralla RJ, Rittemberg C, Peralta M, Lettow L, Cronin M: Cisplatin and • emesis: aspects of treatment and a new trial for delayed emesis using oral dexamethasone plus ondansetron beginning at 16 hours after cisplatin. Oncology 1996. 53 (suppl 1):86-91. A pilot study showing that the combination of ondansetron and dexamethasone induced high complete protection from delayed emesis.
12. Gebbia V, Testa A, Valenza R, Cannata G, Tirrito ML, Gebbia N: Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy: a prospective randomized trial. Cancer 1995, 76:1821-1828.
13. Roila F, De Angelis V, Contu A, Scagliotti G, Tateo S, Massidda B, Picece •• V, Cortesi E, Ricci S, Montinari F, Ciccarese G, Tonato M: Ondansetron vs metoclopramide both combined with dexamethasone in the prevention of cisplatin-induced delayed emesis [abstract]. Proc Am Soc Clin Oncol 1996, 15:528. A double-blind study showing that oral ondansetron had similar antiemetic efficacy of metoclopramide when both are combined with dexamethasone in the prevention of cisplatin-induced delayed emesis. Ondansetron seems to be preferred in patients who had acute emesis.
14. The Italian Group for Antiemetic Research: Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995, 332:1-5.
15. The Italian Group for Antiemetic Research: Persistence of efficacy of three antiemetic regimens and prognostic factors in patients undergoing moderately emetogenic chemotherapy. J Clin Oncol 1995, 13:2417-2426.
16. Kaiser L, Warr D, Hoskins P, Latreille J, Lofters W, Yau J, Palmer M, Zee B, Levy M, Pater J: Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994, 12:1050-1057.
17. Koo WH, Ang PT: Role of maintenance oral dexamethasone in prophy• laxis of delayed emesis caused by moderately emetogenic chemotherapy. Ann Oncol 1996, 7:71-74. An open study demonstrating the superiority of dexamethasone with respect to no antiemetic treatment.
18. De Angelis V. Roila F, Campora E, Cognetti F, Sabbatini R, Donati D, Ricci •• S. Salvati F, Cascinu S, Tagliaventi M, Zaniboni A, Del Favero A for the Italian Group for Antiemetic Research: Incidence and pattern of delayed emesis induced by moderately emetogenic chemotherapy [abstract]. Tumori 1996,82:3110. An observational study documenting the incidence and the prognostic factors of delayed emesis in patients submitted to three consecutive cycles of moderately emetogenic chemotherapy.
19. Navari R, Gandara D, Hesketh P, Hall S, Mailliard J, Ritter H, Friedman C, Fitts D on behalf of the Granisetron Study Group: Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatininduced emesis. J Clin Oncol 1995, 13:1242-1248.
20. Italian Group for Antiemetic Research: Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatininduced emesis. Ann Oncol 1995, 6:805-810.
21. Hesketh P, Navari R, Grote T, Gralla R, Hainsworth J, Kris M, Anthony L, •• Khojasteh A, Tapazoglou E, Benedict C, Hahne W for the Dolasetron Comparative Chemotherapy-Induced Emesis Prevention Group: Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol 1996, 14:2242-2249. A large study demonstrating similar efficacy and tolerability of dolasetron and ondansetron.
22. Audhuy B, Cappelare P, Martin M, Cervantes A, Fabbro M, Rivière A, •• Khayat D, Bleiberg H, Faraldi M, Claverie N, on behalf of the European Dolasetron Comparative Study Group: A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer 1996, 32A:807-B13. A large study demonstrating similar efficacy and tolerability of dolasetron and granisetron.
23. Fauser AA, Duclos B, Chemaissani A, Del Favero A, Cognetti F, Diaz • Rubio E, Cortes Funes H, Conte PF, Dressler H: Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. Eur J Cancer 1996, 32A:1523-1529. A study comparing various doses of oral dolasetron with oral ondansetron.
24. Roila F, Tonato M, Ballatori E, Del Favero A: Comparative studies of various antiemetic regimens. Support Care Cancer 1996, 4:270-280.
25. Ettinger DS, Eisenberg PD, Fitts D, Wilson-Lynch K, Yocom K: A double-• blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy. Cancer 1996, 78:144-151. A study showing similar efficacy between a 2 mg single oral dose and a 1 mg twice oral dose in patients submitted to moderately emetogenic chemotherapy.
26. Wymenga ANM, van der Graaf WTA, Wils JA, Siegenbeek van Heukelom • L, van der Linden GHM, Dullemond-Westland AC, Nooy M, van der Heul C, de Bruijn KM, de Vries EGE: A randomized, double-blind, multicentre study comparing daily 2 and 5 mg of tropisetron for the control of nausea and vomiting induced by low-dose cisplatin- or non-cisplatin-containing chemotherapy. Ann Oncol 1996, 7:505-510. A study demonstrating the superiority of 5 mg intravenously with respect to 2 mg intravenously in patients submitted to moderately emetogenic chemotherapy.
27. Thant M, Pendergrass K, Harman G, Modiano M, Martin L, DuBois D, • Cramer M, Hahne W: Double-blind, randomized study of the dose-response relationship across five single doses of IV dolasetron mesylate for prevention of acute nausea and vomiting after cisplatin chemotherapy [abstract]. Proc Am Soc Clin Oncol 1996, 15:533. A study suggesting a 1.8 mg/kg single dose of dolasetron as the optimal dose for the prevention of cisplatin-induced emesis.
28. Harman GS, Omura GA, Ryan K, Hainsworth JD, Cramer MB, Hahne WF: A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis. Cancer Chemother Pharmacol 1996, 38:323-328.
29. Rubenstein E, Kalman L, Hainsworth J, Plezia P, Modiano M, Eisenberg P, Hesketh P, Frieze K, Whitmore J, Cramer M, Hahne W: Dose-response trial across 4 oral doses of dolasetron for emesis prevention after moderately emetogenic chemotherapy [abstract]. Proc Am Soc Clin Oncol 1995, 14:527.
30. Grote T, Pineda L, Modiano M, Whitmore J, Christy-Bittel J, Cramer M, • Hahne W: Dose-response trial across four oral doses of dolasetron mesylate for prevention of acute nausea and vomiting after platinum-containing moderately emetogenic chemotherapy [abstract]. Proc Am Soc Clin Oncol 1996, 15:533. This study showed a 200 mg single oral dose of dolasetron as optimal in the prevention of emesis induced by moderately emetogenic chemotherapy.
31. 3-receptor antagonists: a class effect? Lancet 1996, 347:584-585. A study describing cross-reactive hypersensitivity between two different 5-HT3 receptor antagonists.